A new player enters the KRAS game with Fortress; Gilead picks up once-failed cancer drug from Mologen's fire sale
→ A new player is entering the KRAS race.
The incubator Fortress Biotech has licensed a treatment developed at Columbia University by Jeffrey Rothman and Gary Schwartz and spun into a new company called Oncogenuity. The company says it has plans to broadly go after genetically driven cancers, but the lead drug is in KRAS, the long-studied oncogene that a couple of companies have just recently gained traction in experimentally treating in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
